Insider Buys Additional US$230k In Transcat Stock
Transcat's CEO, President & Director, Jaime Irick, recently purchased US$230k worth of stock at US$101 per share. Despite this buy, the company has seen more insider selling than buying over the last year, with a significant sale by an Independent Director below the current price. While insiders own about 2.5% of the company, the history of sales suggests caution for potential investors.
Maintenance and repair distributors Q3 earnings: Transcat (NASDAQ:TRNS) simply the best
The article reviews Q3 earnings for maintenance and repair distributors, highlighting Transcat (TRNS) as the top performer. Transcat reported a significant increase in revenue, exceeding analyst expectations, driven by strong execution in its Service and Distribution segments. Other companies like WESCO and Fastenal also had strong quarters, while DXP experienced a weaker performance.
Transcat, Inc. (TRNS) stock price, news, quote and history
This article provides a comprehensive overview of Transcat, Inc. (TRNS), including its current stock price, recent performance metrics, and key financial data. It details the company's business operations across its Service and Distribution segments, highlighting its offerings in calibration, repair, and sales of test and measurement instruments for highly regulated industries. The report also includes analyst insights, earnings trends, and valuation measures for Transcat, Inc.
At an average of $101.26 per share, Transcat (TRNS) CEO buys 2,275 shares.
Transcat Inc.'s President and CEO, Jaime A. Irick, purchased 2,275 common shares at a weighted average price of $101.26 per share on November 5, 2026. The shares were acquired in multiple transactions ranging from $100.89 to $101.35. Additionally, Irick reported holding 15,043 restricted stock units which vest on March 31, 2029, and convert to common stock on a one-for-one basis.
Transcat, Inc. Stock 12‑Month Price Target Raised to $110.8, Implies 24% Upside
The average 12-month price target for Transcat, Inc. (TRNS) stock has been raised from $107 to $110.8 by 5 analysts, implying a potential 24% upside from the Nov. 3 closing price. The consensus rating for the stock remains a "Buy," with all 5 covering analysts recommending it.
Why is Transcat (TRNS) stock soaring today
Shares of Transcat (NASDAQ: TRNS) surged by 18.9% after the company reported strong third-quarter 2026 financial results, with total revenue increasing by 18% to $97.1 million and service revenue rising by 23%. The company also exceeded Wall Street's adjusted earnings estimates, delivering $0.64 per share compared to the consensus of $0.45 per share. This positive report has significantly impacted the market's perception of the business, pushing the stock to a new 52-week high.
Transcat shares surge to record as earnings beat estimates, outlook improves (TRNS:NASDAQ)
Transcat (TRNS) shares reached a record high after the company reported better-than-expected quarterly earnings and improved its annual growth outlook. The provider of equipment calibration services and testing instruments saw an 18% increase in revenue to $97.1 million. The company expects continued organic service revenue growth and expanding service gross margins due to increased demand, market-share gains, and operational improvements.
Transcat Q2 Earnings Call Highlights
Transcat (TRNS) reported strong fiscal Q2 2027 results with an 18% increase in consolidated revenue to $97.1 million, driven by demand in calibration services and distribution. The company saw service revenue grow 23%, with 16% organic growth, and increased its full-year service organic revenue growth outlook. Management also highlighted the strategic importance of acquisitions, such as Southeastern Biomedical Associates, and expects continued margin expansion and a path to $500 million in revenue within three to five years.
Transcat Q2 2027 Earnings Call Transcript
Transcat Inc. reported an 18% increase in consolidated revenue to $97.1 million for Q2 2027, driven by strong growth in both service (up 23%) and distribution (up 10%) segments. The company saw a 31% rise in service gross profit, with margins expanding to 34.4%, and adjusted EBITDA increased 23%. Transcat raised its full-year service organic revenue growth outlook to low double digits, fueled by strategic acquisitions like Southeastern Biomedical Associates and ongoing operational improvements.
Transcat 2Q 2026: Revenue $97.09M, Net income $2.41M, EPS $0.25— 10-Q Summary
Transcat (TRNS) reported strong second-quarter 2026 results, with revenue increasing 18% to $97.09 million and net income soaring 90.1% to $2.41 million, resulting in diluted EPS of $0.25. The growth was driven by a 22.6% increase in service revenue, including 15.8% organic growth, reflecting strong customer retention and demand in key regulated markets. Management also raised its FY2027 service organic growth expectation.
Transcat to Attend Upcoming Investor Conferences in November 2026
Transcat, Inc. (Nasdaq: TRNS) announced its management will attend two investor conferences in November 2026: the Baird Global Industrial Conference and the Stephens Annual Investment Conference. President and CEO Jaime Irick and CFO Tom Barbato are scheduled to host one-on-one meetings with institutional investors at both events, and will also deliver an in-person presentation at the Baird conference on November 11, 2026. This participation aims to engage with the investment community regarding Transcat's position as a leading provider of test measurement, control, and calibration services.
Is the Options Market Predicting a Spike in Transcat Stock?
The options market suggests a potential significant move for Transcat, Inc. (TRNS) stock, with high implied volatility observed in the Jan. 15, 2027 $40 Call. Despite this, analysts currently rate Transcat as a Zacks Rank #3 (Hold), indicating that the high implied volatility might be an opportunity for options traders to sell premium, expecting the stock not to move as drastically as anticipated.
Transcat to Attend Upcoming Investor Conferences in November
Transcat, Inc. announced that its management, including President and CEO Jaime Irick and CFO Tom Barbato, will attend the Baird 2026 Global Industrial Conference and the 2026 Stephens Annual Investment Conference in November 2026. They are scheduled to host one-on-one meetings with institutional investors and present at the Baird conference. The conferences provide an opportunity for Transcat to engage with the investment community regarding its role as a leading provider of test measurement, control, and calibration services.
Transcat Q1 Earnings Call Highlights
Transcat (TRNS) reported strong first-quarter fiscal 2027 results, with revenue up 22% year-over-year, driven by double-digit growth in both calibration services and distribution segments. The company's new CEO, Jaime Irick, outlined a focus on operational excellence, including leveraging technology and AI, while emphasizing strategic acquisitions and growth in the higher-margin rental business as key priorities. Despite some margin normalization in the distribution segment, Transcat expects continued high-single-digit organic service revenue growth and gross-margin expansion for the full fiscal year.
Transcat, Inc. (TRNS) Seasonal returns chart - Yahoo Finance
The article provides a seasonal returns chart for Transcat, Inc. (TRNS) on Yahoo Finance. It displays the average monthly price return for TRNS from 2016 to 2026, with options to view data over 3, 5, 10, or 20 years. The current stock price and pre-market activity are also noted, along with an announcement for an upcoming Q2 2027 earnings call.
Transcat's Service Surge Faces Its First Real Test As Bearish Sentiment Builds
Transcat (TRNS) faces a critical fiscal second-quarter report as bearish sentiment builds despite strong recent performance, including a near doubling of service organic growth. The market expects earnings to contract even with double-digit sales growth, highlighting concerns about margin pressures and the durability of service segment improvements. The upcoming report on November 3 will test whether the company's service engine can maintain its momentum and validate the new CEO's operational-excellence agenda.
Transcat, Inc. Estimates – NASDAQ:TRNS
This article provides access to financial actuals and analyst estimates for Transcat, Inc. (NASDAQ:TRNS). Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform also offers tools for technical analysis, forecasts, and various fundamental stats.
Transcat, Inc. Estimates – LSX:923106
This article provides an overview of Transcat, Inc.'s financial estimates and actuals, accessible through TradingView. It allows users to explore reported financial data and analyst estimates across various statements and visualize trends. The platform also offers tools for comparing actual results with average, high, and low estimates.
Transcat (Nasdaq:TRNS) - Stock Analysis
This Simply Wall St analysis provides an overview of Transcat (TRNS), highlighting its current market valuation, future growth prospects, and recent financial performance. The report notes that TRNS is considered 21.5% undervalued with earnings forecast to grow 35.55% per year, though it also points out risks such as large one-off financial items and significant insider selling. Recent news includes upcoming Q2 2027 results and discussions on the company's M&A strategy and recurring service growth.
Northland upgrades Transcat stock rating on valuation, support By Investing.com
Northland has upgraded Transcat Inc. (NASDAQ:TRNS) to Outperform from Market Perform, maintaining a $95.00 price target, citing the stock's valuation and technical support. Despite appearing overvalued by some metrics, the company's strong fundamentals, including 20.91% revenue growth, and recent positive earnings revisions support the premium. Transcat is set to report its second-quarter fiscal 2027 results on November 17th.
Northland upgrades Transcat stock rating on valuation, support By Investing.com
Northland has upgraded Transcat Inc. (NASDAQ:TRNS) to Outperform from Market Perform, maintaining a $95.00 price target, citing valuation and technical support levels. Despite appearing overvalued by some metrics, the company's strong fundamentals, including 20.91% revenue growth and recent upward earnings revisions, justify the premium valuation. Transcat is set to report its second-quarter fiscal 2027 results on November 17th, following strong first-quarter performance.
Northland upgrades Transcat stock rating on valuation, support
Northland has upgraded Transcat Inc. (NASDAQ:TRNS) to Outperform from Market Perform, maintaining a $95.00 price target, citing the stock's current valuation and technical support levels. Despite appearing overvalued by some metrics, the company's strong fundamentals and impressive revenue growth of 20.91% over the last twelve months support the premium. Transcat is scheduled to report its second-quarter fiscal 2027 results on November 17th.
Transcat Price Target Maintained With a $95.00/Share by Northland Capital Markets
Northland Capital Markets has reiterated its "Outperform" rating on Transcat (NASDAQ: TRNS) and maintained its price target at $95.00 per share. This indicates continued confidence from the firm in the company's future performance.
Transcat to Host Second Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, November 3, 2026 at 4:30 p.m. Eastern Time
Transcat, Inc. announced it will release its second quarter fiscal year 2027 results on Tuesday, November 3, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial and operating results, corporate strategy, and outlook. A telephonic replay and webcast archive will be available following the call.
Transcat to Host Second Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, November 3, 2026 at 4:30 p.m. Eastern Time
Transcat, Inc. (Nasdaq: TRNS) announced it will release its second quarter fiscal year 2027 results on Tuesday, November 3, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial and operating results, corporate strategy, and outlook. Details for joining the call and accessing the webcast replay have been provided.
Transcat buys USD 12.80 million firm while Transcat stock trades at EUR 72.00
Transcat (TRNS) acquired Southeastern Biomedical Associates for USD 12.80 million on August 31, 2026, expanding its reach into regulated biomedical markets. The company's stock was trading at EUR 72.00 on October 20, 2026, with a market capitalization of USD 755.1 million. Transcat reported fiscal first-quarter 2027 revenue of USD 92.95 million and is expected to announce fiscal second-quarter 2027 results on November 2, 2026.
Maintenance and Repair Distributors Stocks Q2 Recap: Benchmarking Transcat (NASDAQ:TRNS)
This article provides a Q2 recap for maintenance and repair distributors stocks, focusing on Transcat (NASDAQ:TRNS). It highlights how supply chain and inventory management themes are impacting the sector and reviews the performance of several companies including Transcat, VSE Corporation, Fastenal, WESCO, and Distribution Solutions, noting their revenue growth and market reactions.
Maintenance and Repair Distributors Stocks Q2 Recap: Benchmarking Transcat (NASDAQ:TRNS)
This article reviews the Q2 performance of several maintenance and repair distributors, focusing on Transcat (NASDAQ:TRNS) which exceeded analysts' revenue expectations but saw its stock decline. It also covers VSE Corporation (NASDAQ:VSEC), Fastenal (NASDAQ:FAST), WESCO (NYSE:WCC), and Distribution Solutions (NASDAQ:DSGR), highlighting their revenue growth and market reactions. The sector generally reported strong Q2 results with revenues beating consensus estimates.
Maintenance and Repair Distributors Stocks Q2 Recap: Benchmarking Transcat (NASDAQ:TRNS)
This article provides a Q2 recap for maintenance and repair distributors stocks, focusing on Transcat (TRNS). It highlights strong revenue beats across the sector, with Transcat leading in analyst estimate beats and VSE Corporation showing the fastest revenue growth. Fastenal, despite a weaker performance against estimates, still reported good results, while WESCO and Distribution Solutions also demonstrated strong quarterly performances.
Transcat stock fell below its 200-day moving average
Transcat (TRNS) stock recently fell below its 200-day moving average to $80.35, despite reporting strong Q2 2026 revenue growth of 21.6% to $92.95 million. Analysts have lowered ratings, citing valuation concerns, although the company's core business of calibration and testing services continues to show operating improvement. The market is now focused on whether revenue growth can translate into stronger profitability, given the current 0.99% net margin.
Transcat stock trades at EUR 73.50 with USD 771.0 million value
Transcat stock is trading at EUR 73.50, with a market capitalization of USD 771.0 million. The company reported quarterly revenue of USD 92.95 million, a 21.6% increase year-over-year, and earnings per share of USD 0.51, exceeding analyst estimates. Northland Securities has set a price objective of USD 95.00 for the stock.
How Transcat Inc. (TRNS) Affects Rotational Strategy Timing
This article analyzes Transcat Inc. (TRNS) using AI models, highlighting weak near-term sentiment but strong long-term prospects. It provides three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels, and a multi-timeframe signal analysis for various horizons. The report emphasizes the potential for choppy conditions due to divergent sentiment.
Transcat grants 1,671 RSUs while analysts rate Transcat stock Reduce
Transcat (TRNS) granted 1,671 restricted stock units to director Gary J. Haseley on September 9, 2026, while analysts maintain a "Reduce" rating on the stock. The company's latest earnings report showed strong performance, with earnings per share of $0.51 against a $0.38 consensus and revenue of $92.95 million surpassing the $86.55 million expectation. Despite the positive financial results, Northland Securities lowered its rating to "Market Perform," and the overall analyst consensus remains "Reduce" with a $95.00 price target.
Transcat stock enters investor meetings after earnings beat estimates
Transcat (TRNS) stock is heading into investor meetings after reporting strong quarterly earnings, beating revenue and EPS estimates on August 4, 2026. The company, which provides calibration and repair services, will engage with institutional investors at upcoming conferences, following a 7.4% revenue beat and an EPS of $0.51 against a $0.38 consensus. Despite the positive earnings, the stock was trading below its yearly high, making these investor meetings crucial for future market commentary.
Transcat, Inc. (TRNS) Stock Price, News, Quote & History
This article provides an overview of Transcat, Inc. (TRNS), including its current stock price, recent performance metrics, and key financial data. It details the company's business segments—Service and Distribution—and its offerings in calibration and laboratory instrument services for highly regulated industries. The report also includes analyst price targets and a summary of recent earnings trends.
Transcat stock gains 2.51 percent as growth meets valuation
Transcat stock increased by 2.51 percent, reaching USD 88.16 on September 22, 2026, with a market capitalization of USD 825.161 million. The stock's six-month return was 21.9 percent, outperforming the S&P 500, but its forward P/E of 43.8 highlights the need for earnings growth to keep pace with valuation. While revenue grew at 13.8% annually over five years, EPS growth was only 4.1%, indicating a gap that could impact future appreciation.
Transcat stock holds at USD 86.00 as earnings growth builds
Transcat stock was quoted at USD 86.00 on Nasdaq as of September 21, 2026, with a market capitalization of USD 804.944 million, placing it in the small-cap segment. The article highlights that while the company's historical fiscal year 2021 third-quarter figures show quarterly revenue of USD 217.41 million, it also reported negative earnings of USD 91.18 million, leading to a negative profit margin. The author emphasizes that for a small-cap company like Transcat, earnings quality is a critical analytical variable, and future valuation signals will depend on whether revenue growth translates into positive earnings and a stronger margin.
Transcat, Inc. Announces 2026 Annual Meeting Shareholder Voting Results
Transcat, Inc. (NASDAQ:TRNS) held its annual shareholder meeting on September 9, 2026, and disclosed the voting results on September 10, 2026. Shareholders elected six directors for one-year terms, approved executive compensation in an advisory vote, and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending March 27, 2027. Robert L. Mecca received the most votes among the elected directors.
Hospital equipment services expand across the Southeast in Transcat's $12.8M deal
Transcat (Nasdaq: TRNS) has acquired Southeastern Biomedical Associates for $12.8 million, expanding its biomedical calibration and equipment services across the southeastern United States. This acquisition strengthens Transcat's presence in the life science sector and highly regulated end markets, enhancing its capabilities in accredited calibration, repair, and preventative maintenance for hospital networks and healthcare facilities. The owners of Southeastern Biomedical will remain with Transcat to drive future growth.
RSU awards lift Transcat (TRNS) director to 2,291 shares
Transcat director Robert Mecca's recent equity compensation activity, detailed in a Form 4 filing, shows he received 1,671 Restricted Stock Units (RSUs) on September 9, 2026, which vest on September 9, 2027. On September 10, 2026, 1,587 RSUs vested and converted into common shares, increasing his direct holdings to 2,291 common shares. Additionally, Mecca holds a stock option for 10,000 shares with an exercise price of $98.88, vesting pro rata over five years and expiring on January 24, 2034.
New RSU grant and vesting reported by Transcat (TRNS) director
Transcat (TRNS) director Gary J. Haseley reported equity compensation activity, including a new grant of 1,671 Restricted Stock Units (RSUs) on September 9, 2026, which will vest on September 9, 2027. Additionally, 1,587 previously granted RSUs vested and converted into common stock on September 10, 2026, increasing his direct holdings to 40,689 shares. He also holds 1,200 shares indirectly through family trusts.
Transcat Inc Director Oksana Dominach Reports Stock Sale and RSU Grant in September 2026 SEC Filing
Transcat Inc. Director Oksana S. Dominach reported a stock sale and a restricted stock unit (RSU) grant in a September 2026 SEC filing. Dominach sold 7,312 shares of common stock at $85.5958 per share on September 2, 2026, and subsequently owned 4,346 shares. She also received a grant of 1,587 RSUs, set to vest on September 10, 2026.
Transcat, Inc. acquired Southeastern Biomedical Associates, Inc. for $12.8 million.
Transcat, Inc. (NasdaqGM:TRNS) has acquired Southeastern Biomedical Associates, Inc. for $12.8 million. The acquisition was completed on August 31, 2026. Transcat specializes in accredited calibration, reliability, and maintenance optimization services for highly regulated industries like life science, aerospace, and energy.
Transcat Acquires Southeastern Biomedical Associates For $12.8 Million
Transcat, Inc. has acquired Southeastern Biomedical Associates, Inc. for $12.8 million. The acquisition was reported on August 31, 2026, and is part of Transcat's strategy to expand its service offerings. Transcat specializes in accredited calibration and related services for highly regulated industries.
Transcat Acquires Southeastern Biomedical for $12.8M to Expand Healthcare Services
Transcat Inc. has acquired Southeastern Biomedical Associates Inc. for $12.8 million in cash, expanding its biomedical calibration, equipment repair, and preventive maintenance capabilities, particularly within the healthcare sector. This acquisition strengthens Transcat's presence with hospitals and healthcare facilities across the Southeastern United States. Southeastern's owners, Boyd Campbell and Greg Johnson, will remain with Transcat to help lead the growth of the combined biomedical business, leveraging their three decades of operating experience.
Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical
Transcat, Inc. has acquired Southeastern Biomedical Associates Incorporated for $12.8 million in cash. This acquisition expands Transcat's accredited biomedical calibration capabilities, equipment repair, and preventative maintenance services, strengthening its presence with hospital networks and healthcare facilities in the Southeastern United States. The former owners of Southeastern Biomedical will remain with Transcat to help drive the growth of the combined biomedical business.
Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September
Transcat, Inc. announced its management will participate in three investor conferences in September 2026: the Jefferies Global Industrials Conference, Lake Street Capital Markets BIG10 Conference, and D.A. Davidson Diversified Industrials & Services Conference. President and CEO Jaime Irick and CFO Thomas Barbato will host one-on-one meetings and present at the Jefferies conference. The company aims to engage with institutional investors at these events.
Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September
Transcat, Inc. (Nasdaq: TRNS) announced its management will attend three investor conferences in September 2026: the Jefferies Global Industrials Conference, Lake Street Capital Markets BIG10 Conference, and D.A. Davidson Diversified Industrials & Services Conference. President and CEO Jaime Irick and CFO Thomas Barbato will host one-on-one meetings and a presentation, while Barbato and Director of Finance John Howe will also participate in meetings. The company aims to engage with institutional investors and highlight its leadership in test measurement, control, and calibration services.
Transcat's (NASDAQ:TRNS) Conservative Accounting Might Explain Soft Earnings
The article suggests that Transcat's seemingly soft earnings might be a result of its conservative accounting practices, which could be obscuring the company's true financial health. Investors might be overlooking the underlying strength of the business due to these reporting methods. It implies that a deeper analysis beyond the surface-level earnings report is necessary to understand Transcat's actual performance.
Transcat's (NASDAQ:TRNS) Conservative Accounting Might Explain Soft Earnings
This article suggests that Transcat's seemingly soft earnings might be due to its conservative accounting practices, specifically its approach to capitalizing software development costs. The author argues that if the company were to use a more aggressive accounting method, its reported earnings would appear significantly higher.